glp-1 agonists and retained gastric contents at endoscopy Receptor Gastrointestinal Endoscopy: A Narrative Review of Risks, Management Strategies, and the Need for Clinical Consensus GLP-1s May Lead to an
Description
A comprehensive phase 3 program is ongoing to evaluate efficacy, safety, and cardiovascular/renal outcomes in people with obesity and/or T2D
If you took Januvia, Victoza, Janumet and / or Byetta had side effects & developed pancreatic cancer - contact a diabetes medication lawyer.
Summary Retatrutide, a triple agonist now in phase 3 trials, has the potential to become the most effective pharmacological treatment for obesity while also offering substantial benefits in T2D management and other cardiometabolic risk factors.
The approval could expand access to an effective therapy for managing obesity.
Add psoriatic arthritis | 47 comments on LinkedIn
